Australia backs Pfizer virus vaccine over AstraZeneca for under-50s
Australia's Chief Medical Officer, Paul Kelly, told reporters the risk of clots was extremely low.08-04-2021
08-04-2021
US begins study assessing allergic reactions to Pfizer, Moderna vaccines
Data from the study, which is sponsored and funded by the NIAID, is expected to be released in late summer08-04-2021
PFIZER LTD. - 500680 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayPFIZER LTD. 2CINL24231MH1950PLC008311 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NOTAPPLICABLE 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: PRAJEET NAIR Designation: COMPANY SECRETARY EmailId: prajeet.nair@pfizer.com Name of the Chief Financial Officer: MILIND PATIL Designation: EXECUTIVE DIRECTOR FINANCE AND CHIEF FINANCIAL OFFICER EmailId: milind.anil.patil@pfizer.com Date: 07/04/2021 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.07-04-2021
PFIZER LTD. - 500680 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) and other application regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agent of the Company, KFin Technologies Private Limited has received request for issue of duplicate Share Certificate(s) from the Shareholders as per the enclosed letter.05-04-2021
Pfizer/BioNTech COVID-19 vaccine 91% effective in updated data, protective against South African variant
Pfizer's CEO Albert Bourla said the updated result positions the drugmakers to submit for full US regulatory approval for the vaccine against COVID-19.02-04-2021
Pfizer Ltd - 500680 - Closure of Trading Window
We would like to inform you that, for the purpose of declaration of financial results of the Company, for the quarter and year ended March 31, 2021, the trading window of the Company shall remain closed from March 31, 2021 (close of business) till 48 hours after the results are made public. We request you to kindly take the above on record.31-03-2021
BioNTech-Pfizer says its Covid-19 vaccine effective on 12-15 year olds
In a study of 2,260 U.S. volunteers ages 12 to 15, preliminary data showed there were no cases of COVID-19 among fully vaccinated adolescents compared to 18 among those given dummy shots31-03-2021
COVID-19 vaccine: Pfizer, Moderna jabs 90% effective after both doses, says US study
The risk of infection fell 90% by two weeks after the second shot, the study of nearly 4,000 US healthcare personnel and first responders found30-03-2021
Pfizer, BioNTech start testing COVID-19 vaccine in children under 12
Nearly 66 million doses of the vaccine had been administered in the United States as of Wednesday morning, according to data from the US Centers for Disease Control and Prevention26-03-2021
Pfizer vaccine less or moderately effective against South African Covid variant: Study
But it can neutralise the British variant and the wild-type strain of the virus25-03-2021